Zynerba Pharmaceuticals

    [td_text_with_title custom_title=”About”]Our mission is to improve the lives of patients battling severe health conditions including epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain through these therapeutics.
    Our development pipeline includes patent-protected synthetic transdermal cannabinoid products, which we believe will provide new treatment options for patients as well as additional treatment options for patients not currently receiving adequate relief or otherwise experiencing intolerable side effects from current treatment regimes.

    CBD Gel – ZYN002
    ZYN002 is the first and only synthetic CBD, a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery. We are studying ZYN002 in patients with refractory epilepsy, Fragile X syndrome and osteoarthritis.

    THC Pro-Drug Patch – ZYN001
    ZYN001 is a pro-drug of THC that enables transdermal delivery via a patch. We are studying ZYN001 in patients with fibromyalgia and peripheral neuropathic pain.[/td_text_with_title]

    [td_text_with_title custom_title=”Latest post”]

    Zynerba Pharmaceuticals files for a $58 million IPO

    Zynerba Pharmaceuticals, a preclinical biotech developing cannabinoid-based therapies for osteoarthritis and epilepsy, filed on Wednesday with the SEC to raise up to $58 million in an initial public offering. The Devon, PA-based company, which was founded in 2007, plans to list on the NASDAQ under the symbol ZYNE. Zynerba Pharmaceuticals initially filed confidentially on January 12, […]